EDITOR'S NOTE
The following material was provided to the attendees of the workshop and to "All NDA Applicants" by Harry M. Meyer, Jr., MD, Food and Drug Administration.
The Drug Information Association is pleased to provide this material to its membership.
Thomas W. Teal
Editor-in-Chie f Drug In formation Journal A guideline for postmarketing reporting of adverse drug reactions was distributed in July 1985 with an official issuance date of August 23. Based on comments received, particularly following a large workshop held with industry on August 6 and 7, several areas of further clarification are needed now. For this reason, the questions and answers listed below are issued.
Our plan is to redraft the guidelines in January 1986, after actual experience with their use. Thus, the questions and answers below are bridging statements that are intended to provide interim guidance to applicants. Page numbers in the questions and answers refer to the guidelines. Question 1: What does "life-threatening" mean in the definition of a serious reaction (event) (p. 3)?
Answer: For purposes of the guideline, "lifethreatening" refers to a reaction (event) associated with one or more of the following: death, new hospitalization, prolonged hospitalization. Thus, a serious reaction (event) is one that is associated with one or more of the following: death, new hospitalization, prolonged hospitalization, permanent or severe disability, prescription drug therapy, congenital anomaly, cancer, or overdose.
Question 2: When do overdoses have to be reported (p. 2)?
Answer: Only overdoses which are associated with adverse reactions (events) need to be reported. If no adverse event occurs, the fact alone of overdose need not be reported.
If the resultant or associated reaction is unlabelled, then a 15-day report must be filed; if labelled, then the report is filed within the Periodic Report.
Question 3: What constitutes "significant" in the definition of failure to produce the expected pha.rmacologic action and when should reports involving this be filed (p. 3)?
Answer: When a report of failure to produce the expected pharmacologic action is associated with a serious, unlabelled reaction (event), it is deemed significant and a 1639 form should be completed and submitted as a 15-day report. In all other instances, no submission of such reports should be made unless an increased frequency (of failure to produce the expected pharmacologic action) is found (as defined in the regs and guideline). When increased frequency of failure of pharmacologic action is found, it must be submitted, in narrative form, within 15 days of detection. No 1639 forms for failure of pharmacologic action should be submitted in the Periodic Report.
Question 4 What modifications in the 1639 form will automatically be allowed (p. 4)?
Answer: The following modifications are allowed : a. Title: "Drug Experience" or "Drug Event" may replace "Adverse Reaction." b. Reaction: Wherever the term "Reaction" appears, it may be replaced by "Event." c. Suspect: Wherever the term "Suspect" appears, it may be replaced by "Associated. Question 5: What should be done when adverse events (reactions) are found for a competitor's drug during a controlled study?
Answer: Generally reactions to a competitor's drug should be reported to the manufacturer of the drug. The allowed exception will be in the case of a controlled study in order to protect competitive information. In this instance, 15-day type reports (serious, unlabelled events or increased frequency of serious labelled events) associated with a competitor's product may be made directly to the FDA.
Question 6: When does the 15-day clock start running?
Answer: The 15-day clock begins when the applicant receives information indicating that a reported reaction fulfills the criteria for filing a 15-day report, i.e., that a serious, unlabelled reaction has been received or that a serious, labelled reaction has been reported at increased frequency. Applicants must be prepared to show (on the FDA's request) that rapid followup to determine outcome was done. If outcome (death or hospitalization or treatment or disability) and therefore whether the reaction is serious cannot be determined, the report should be submitted in the periodic report. When a serious outcome has been found for an unlabelled reaction, the 1639 form must be submitted within 15-days of the date of that determination. If a blinded study is being done, reports should be made only when the code is broken; i.e., within 15-days after the code is broken and serious unlabelled reactions are found.
Question 7:
For an unlabelled reaction when the outcome is unknown, but which sounds as if it may be serious, when does the 15day clock begin?
Answer: Every effort should be made to obtain outcome information. If such information cannot be obtained, the ADR should be submitted with the Periodic Report. If the reaction is later found to be both serious and unlabelled, the 15-day time period begins with receipt of this follow-up information.
Question 8: What are the reporting requirements for holders of generic drug applications (ANDAs)?
Answer: The reporting requirements apply equally to ANDAs and to NDAs. ANDA holders are required to report quarterly for the first 3 years of marketing and annually thereafter and are required to submit 15day reports as described in the regulations. Applicants holding ANDAs approved between August 22, 1982 and August 22, 1985, should report annually except for those products which are classified as new chem-ical entities; this latter group must report quarterly until 3 full years have passed since marketing.
Question 12: What information submitted under 314.80 is subject to release under the Freedom of Information Act?
Question 9: Does the regulation apply to non-applicants whose names appear on the label as a manufacturer, packer or distributor?
Answer: Yes. See 314.80(c)(l)(iii). Such non-applicants may submit reports to the FDA or can submit them within 3-days to the applicant who, in turn must submit them to the FDA.
Question 10: If different formulations of a product are covered by different NDA's, how are adverse reaction reports to be handled?
Answer: A Periodic Report is required for each NDA. Reports should be submitted in the Periodic Report for the suspect drug identified. If the drug cannot be specifically identified the 1639 should be filed in only one of the Periodic Reports and referenced in the other reports.
Question 11: Is the starting date for reporting the date of marketing (as given in the guidelines, p. 3) or the date of approval of an application (as stated in the regs.)?
Answer: The Federal regulations, paragraph 314.80(~)(2), give the Agency the authority to extend the quarterly reporting requirements. Therefore, requirement of the use of the marketing date in the guidelines should be interpreted as an amendment and extension of the quarterly reporting requirements. In summary, quarterly reports should be filed for three years after marketing.
Answer: All submitted information is subject to release except names and any information that would identify the person using the product and any third party involved with the report such as a physician, hospital or other institution [see 21 C.F.R. 3 14.430(e)(4)].
Question 13: Must the time periods for comparison for increased frequency given in the guidelines always be used?
Answer: Yes, as a minimum. If other time periods are used they should be explained.
Question 14:
Can statistical methods other than those given in the guidelines be used to determine and analyze increased frequency?
Answer: Yes, any appropriate statistical method used should be described. Examples include: 
